FDA greenlights first all-oral, fixed-duration combo therapy for untreated CLL patients

The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy

Johnson & Johnson bags FDA nod for monthly RYBREVANT FASPRO dosing in advanced lung cancer

This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care

BioAsia 2026 cements Telangana’s global leadership in TechBio and life sciences

40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions

Merck, Mayo Clinic forge AI powerhouse to accelerate drug discovery

Asahi Kasei Pharma & Alchemedicine launch first human trials for hard-to-treat diseases drugs

European Commission greenlights higher-dose Wegovy for obese adults

Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose

LEX Diagnostics gets FDA nod and CLIA waiver for ultra-fast VELO system

The VELO system supports multiplex testing for Influenza A, Influenza B, and COVID-19, producing PCR results in six to ten minutes

QCIL to build 350+ bed state-of-the-art CARE Hospital in Nagpur

Lupin partners with Spektus Pharma to commercialize DeslaFlex antidepressant in Canada

DeslaFlex is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab oral drug-delivery platform

Roche’s Gazyva hits major milestone in rare kidney disease

Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units